TGFB1 and pulmonary fibrosis: In summary, our results show that JAK1/2 inhibitor baricitinib had the efficacy on restraining pulmonary fibrosis progression by suppressing TGF-β1-induced fibroblasts activation and epithelial injury (Figure 10).